GB2458868B - Fluphenazine based combination for use in the treatment of protein aggregation diseases - Google Patents

Fluphenazine based combination for use in the treatment of protein aggregation diseases

Info

Publication number
GB2458868B
GB2458868B GB0914423A GB0914423A GB2458868B GB 2458868 B GB2458868 B GB 2458868B GB 0914423 A GB0914423 A GB 0914423A GB 0914423 A GB0914423 A GB 0914423A GB 2458868 B GB2458868 B GB 2458868B
Authority
GB
United Kingdom
Prior art keywords
fluphenazine
treatment
protein aggregation
based combination
aggregation diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0914423A
Other versions
GB2458868A (en
GB2458868A8 (en
GB0914423D0 (en
Inventor
Stuart Mark Wilson
Christopher John Stanley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PAD Pharma Ltd
Original Assignee
PAD Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PAD Pharma Ltd filed Critical PAD Pharma Ltd
Publication of GB0914423D0 publication Critical patent/GB0914423D0/en
Publication of GB2458868A publication Critical patent/GB2458868A/en
Publication of GB2458868A8 publication Critical patent/GB2458868A8/en
Application granted granted Critical
Publication of GB2458868B publication Critical patent/GB2458868B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB0914423A 2007-02-01 2008-01-30 Fluphenazine based combination for use in the treatment of protein aggregation diseases Expired - Fee Related GB2458868B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0701970.6A GB0701970D0 (en) 2007-02-01 2007-02-01 Treatment of protein aggregation diseases
GBGB0704105.6A GB0704105D0 (en) 2007-02-01 2007-03-02 Treatment of protein aggregation diseases
PCT/EP2008/051134 WO2008092898A1 (en) 2007-02-01 2008-01-30 Treatment of protein aggregation diseases

Publications (4)

Publication Number Publication Date
GB0914423D0 GB0914423D0 (en) 2009-09-30
GB2458868A GB2458868A (en) 2009-10-07
GB2458868A8 GB2458868A8 (en) 2009-11-04
GB2458868B true GB2458868B (en) 2011-04-06

Family

ID=37891147

Family Applications (3)

Application Number Title Priority Date Filing Date
GBGB0701970.6A Ceased GB0701970D0 (en) 2007-02-01 2007-02-01 Treatment of protein aggregation diseases
GBGB0704105.6A Ceased GB0704105D0 (en) 2007-02-01 2007-03-02 Treatment of protein aggregation diseases
GB0914423A Expired - Fee Related GB2458868B (en) 2007-02-01 2008-01-30 Fluphenazine based combination for use in the treatment of protein aggregation diseases

Family Applications Before (2)

Application Number Title Priority Date Filing Date
GBGB0701970.6A Ceased GB0701970D0 (en) 2007-02-01 2007-02-01 Treatment of protein aggregation diseases
GBGB0704105.6A Ceased GB0704105D0 (en) 2007-02-01 2007-03-02 Treatment of protein aggregation diseases

Country Status (3)

Country Link
US (1) US8383617B2 (en)
GB (3) GB0701970D0 (en)
WO (1) WO2008092898A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US8809617B2 (en) 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
DE102010062810B4 (en) 2010-09-07 2014-03-13 Immungenetics Ag 2- (R2-thio) -10- [3- (4-R1-piperazin-1-yl) -propyl] -10H-phenothiazines for the treatment of neurodegenerative diseases selected from beta-amyloidopathies and alpha-synucleinopathies
GB201904810D0 (en) 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases
KR102306867B1 (en) * 2019-10-08 2021-09-28 성균관대학교산학협력단 Inhibitor of protein aggregates

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004915A1 (en) * 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
WO2001012174A1 (en) * 1999-08-13 2001-02-22 Vela Pharmaceuticals Inc. Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
US20030108551A1 (en) * 2001-11-02 2003-06-12 Nicolau Yves Claude Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins
WO2004058258A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2005063254A2 (en) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2006007864A1 (en) * 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
WO2006007614A1 (en) * 2004-07-21 2006-01-26 Roland Kirchberger Two-stroke internal combustion engine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554736A (en) * 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
US3058979A (en) * 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
FR1470818A (en) * 1966-03-08 1967-02-24 Vysshee Voennoe Inzh Tekhn Kra Instrument for measuring the parameters of mechanical oscillations
CA962021A (en) * 1970-05-21 1975-02-04 Robert W. Gore Porous products and process therefor
US4310524A (en) * 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
PH25025A (en) 1986-12-17 1991-01-28 Glaxo Group Ltd A method of treating dementia and other cognitive disorders using 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)methyl)-4h-carbazol-4-one
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
JP4108747B2 (en) 1995-07-13 2008-06-25 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Piperazine derivatives as therapeutic agents
WO1997016191A1 (en) 1995-11-02 1997-05-09 Warner-Lambert Company Inhibition of amyloidosis by 9-acridinones
UA56185C2 (en) * 1996-09-30 2003-05-15 Пфайзер Інк. Aralkyl- and aralkylidene heterocyclic lactams and imids, a pharmaceutical composition and a treatment method
AUPO274596A0 (en) 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US5869500A (en) * 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
WO1999025339A1 (en) 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
DK0957099T3 (en) * 1998-04-15 2003-03-17 Pfizer Prod Inc Heterocyclic carboxamides
WO2002038141A2 (en) 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Compositions and methods for treatment of mild cognitive impairment
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
WO2002053104A2 (en) * 2001-01-02 2002-07-11 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
ES2564293T5 (en) 2002-02-28 2019-04-04 Microsens Biophage Ltd Enlazamiento of pathological forms of prion proteins
AU2003298664A1 (en) 2002-11-20 2004-06-15 Cypress Bioscience, Inc. Treatment of cognitive dysfunctions'
AU2003276107A1 (en) * 2003-04-24 2004-11-19 Universitat Zurich Method of monitoring immunotherapy
PT1470818E (en) * 2003-04-25 2006-11-30 Neuro3D Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns
CA2576153A1 (en) 2004-08-05 2006-02-16 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004915A1 (en) * 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
WO2001012174A1 (en) * 1999-08-13 2001-02-22 Vela Pharmaceuticals Inc. Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
US20030108551A1 (en) * 2001-11-02 2003-06-12 Nicolau Yves Claude Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins
WO2004058258A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2005063254A2 (en) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2006007864A1 (en) * 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
WO2006007614A1 (en) * 2004-07-21 2006-01-26 Roland Kirchberger Two-stroke internal combustion engine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cellular and mollecular neurobiology, vol. 22, No.5-6 [2002], De Felice et al, "beta Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease", pages 545-563, especially page 557 *
Journal of Neurochemistry vol 98, no.3, [2006] Klingenstein et al, "Tricyclic antidepressants, quinacrine and a novel synthetic chimera thereof clear prions by destabilising detergent resistant membrane compartments" pages748-759 especially page 756 *

Also Published As

Publication number Publication date
GB2458868A (en) 2009-10-07
WO2008092898A1 (en) 2008-08-07
GB2458868A8 (en) 2009-11-04
US20100035859A1 (en) 2010-02-11
GB0701970D0 (en) 2007-03-14
US8383617B2 (en) 2013-02-26
GB0914423D0 (en) 2009-09-30
GB0704105D0 (en) 2007-04-11

Similar Documents

Publication Publication Date Title
HK1162031A1 (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases bcl-2
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
SI2254869T1 (en) Neue 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 und p40
IL232325A0 (en) 18-methyl-6'7-methylene-3-oxo-17-pregn-4-ene-21,17b-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis
IL216967B (en) 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives and use thereof for the treatment of diseases
EP2219448A4 (en) Therapeutic compounds and their use in treating diseases and disorders
PT2101731T (en) Endoxifen for use in the treatment of cancer
PL2148667T3 (en) Use of cyclohexanehexol derivatives in the treatment of ocular diseases
LT2262778T (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
IL202424A (en) Telomerase activating compounds for use in treating diseases, disorders and conditions related thereto
IL196745A (en) Idebenone for use in transmucosal administration for use in the treatment of diseases
GB2458868B (en) Fluphenazine based combination for use in the treatment of protein aggregation diseases
HK1168283A1 (en) Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto sorcs1
ZA201108106B (en) Use of phthalimide derivatives in the treatment of diseases
GB0619816D0 (en) Novel interferon-alpha constructs for use in the treatment of cancer
HRP20151393T8 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
GB201020621D0 (en) Pin for hygienic and/or medical use in the anal region
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
HK1172568A1 (en) Soluble pharmaceutical forms of n,n-diaminodiphenyl sulphone for optimum use in the treatment of various diseases nn-
IL201880A0 (en) Klotho protein and related compounds for the treatment and diagnosis of cancer
GB0526423D0 (en) Treatment of protein aggregation diseases
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis
IL198070A (en) Sirna for use in the treatment of ischemia-reperfusion injury
GB0700755D0 (en) The Treatment of ophthalmic diseases

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20140130